Dr. Michael Streit
Michael Streit, MD, MBA joined Janssen on 24 June 2013 as Clinical Leader, Early Development to support the Hematology and Prostate Cancer early-development activities.
Michael has a strong and diverse background in biomedical sciences. He received his medical training in Hematology/Oncology from the Free University in Berlin. Michael went on to complete a three-year post‐doctoral research fellowship at the Cutaneous Biology Research Center at the Massachusetts General Hospital where he also served as research instructor at Harvard Medical School.
His first industry assignment was to work as a laboratory‐based Oncology Discovery scientist at Berlex Biosciences the US-subsidiary of Schering AG (now part of Bayer). He subsequently received an MBA from Golden Gate University and joined Boehringer‐Ingelheim to conduct early and late clinical trials in lymphoma, pancreatic and lung cancer patients. In 2008, he moved to Bristol‐Myers Squibb (BMS) and led several global Phase 3 trials in hepatocellular carcinoma for the antiangiogenic agent, brivanib. In addition, Michael was also the co‐leader of their Biomarker Working Group focused on preclinical and clinical translational research. In 2010, he joined GlaxoSmithKline (GSK) Oncology to work on the MEK inhibitor trametinib and the BRAF-inhibitor dabrafenib. Michael was the physician leader of the US and EU filing of trametinib and co-leader of the US-filing of the first combination therapy of two targeted small molecule inhibitors (i.e. trametinib and dabrafenib). Both new medicines were approved by the FDA in May 2013.
Since Joining Janssen, Michael has worked on a number of first-time-in-human programs such as the listeria-based immunotherapies (ADU-214 and ADU-741) and the first –T-cell re-direction antibody (i.e. MGD-011). Currently, Michael is the medical lead of the agonistic anti-CD40 antibody program and primarily supports the activities of the Prostate DAS.